MAY 08, 2019 12:49 PM PDT

Drug for Huntington Disease Successfully Lowers Culprit Protein

WRITTEN BY: Nouran Amin

In a study published in the New England Journal of Medicine, a drug for the first time was shown to successfully lower the abnormal protein that causes the debilitating Huntington disease (HD) in patients without any adverse reactions. The culprit protein is mutant huntingtin protein that becomes toxic in the central nervous system of Huntington disease patients.

https://hdsa.org/wp-content/uploads/2019/03/what_is_hd_overview_hd_disease_full.jpg

“HD affects the whole brain, but certain areas are more vulnerable than others. Pictured above are the basal ganglia – a group of nerves cell clusters, called nuclei. These nuclei play a key role in movement and behavior control and are the parts of the brain most prominently affected in early HD.”

Credit: hdsa.org

The study is clinical trial designed to see if the drug halts or slows down progression of Huntington disease. The drug, sponsored by Ionis Pharmaceuticals and Hoffmann-La Roche, was administered monthly to 34 early HD patients via an injection directly into the cerebrospinal fluid (CSF)—which is the location of the protein.

"This is a tremendously exciting and promising result for patients and families affected by this devastating genetic brain disorder," said Dr. Blair Leavitt, neurologist and director of research at the Centre for Huntington Disease at UBC. "For the first time, we have evidence that a treatment can not only decrease levels of the toxic disease-causing protein in patients, but that it is also safe and very well tolerated."

Learn more about Huntington Disease (HD):

Huntington disease (HD) develops adulthood and progresses to causes abnormal involuntary movements, psychiatric symptoms and dementia. It is a fatal a genetic neurological disease caused by a single known mutation. There is currently no effective treatments that have been proven to slow the progression of the disease.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 15, 2019
Microbiology
JUN 15, 2019
Potential New Antibiotic is Made by an Insect-linked Microbe
Like many other organisms, bacteria have to compete for resources and have developed a wide array of strategies to use, including antibiotics....
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Combination Immunotherapy Stops Liver Cancer Growth
The number of individuals diagnosed with liver cancer is on the rise and current therapies are largely ineffective. However, new preclinical data from the ...
JUN 15, 2019
Genetics & Genomics
JUN 15, 2019
The Power and Responsibility of Using CRISPR
      What makes CRISPR so powerful is that it is easy for any molecular or genetic scientist to use, and it works on almost every cell...
JUN 15, 2019
Health & Medicine
JUN 15, 2019
FDA Approves New Osteoporosis Drug for Post-Menopausal Women
The U.S. Food and Drug Administration recently approved a new treatment to combat osteoporosis in high-risk postmenopausal women. Osteoporosis is a disease...
JUN 15, 2019
Genetics & Genomics
JUN 15, 2019
Clinical Trials Aim to Improve Therapeutics with Genomic Data
Scientists now have access to vast amounts of human genetic data. Now the NIH wants to put that data to use....
JUN 15, 2019
Drug Discovery
JUN 15, 2019
Novel Treatments for Auto-immune Disorders
A recent research study examined a library of almost 300,000 small molecules to search for a molecule that may be a potential target for the human GMP-AMP ...
Loading Comments...